Tanox

In the 1980s, Tanox scientists discovered a novel approach for the treatment of allergic disease by reducing the levels of immunoglobulin E (IgE) in the blood. IgE is one of a class of antibodies that is responsible for causing allergic reactions. In June 2003, an anti-IgE therapy, Xolair® (Omalizumab) For Subcutaneous Use, received approval from the U.S. Food and Drug Administration for the treatment of adults and adolescents (12 years of age and above) with moderate-to-severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. In October of 2005, Xolair was approved for marketing in all 25 European Union states and is the first monoclonal antibody approved for the treatment of asthma in Europe. Tanox is committed to becoming a world leader in providing effective therapies for immune-mediated diseases, infectious disease, inflammation and cancer. Through the development and use of innovative technologies, we create products that address unmet medical needs by treating the underlying cause of disease.

Contact Details: 10555 Stella Link Houston TX 77025-5631 United States of America Tel: 713-578-4000 Fax: 713-578-5000 Email: info@tanox.com WWW: www.tanox.com/

Loading...

Recent Publications by Tanox:
Fungal proteases induce Th2 polarization through limited dendritic cell maturation and reduced production of IL-12. Allergens are capable of polarizing the T cell immune response toward a...	5th June, 2008	Tanox,	J Immunol. 2008 May 1;180(9):6000-9.
Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3. The Notch pathway regulates the development of many tissues and cell types...	13th May, 2008	Tanox, Incorporated,	J Biol Chem. 2008 Mar 21;283(12):8046-54. Epub 2008 Jan 8. DOI Direct Link
Enhanced cell culture performance using inducible anti-apoptotic genes E1B-19K and Aven in the production of a monoclonal antibody with Chinese hamster ovary cells. Mammalian cells are used for the production of numerous biologics...	18th July, 2007	Cell Culture Sciences, Tanox, Inc., Houston, Texas, USA.	Biotechnol Bioeng. 2007 Jul 1;97(4):877-92. DOI Direct Link
Mast cell and immune inhibitory receptors. Modulation by balancing activating and inhibitory receptors constitutes an...	1st April, 2006	Tanox, Inc. 10555 Stella link, Houston, Texas 77025, USA.	Cell Mol Immunol. 2004 Dec;1(6):408-15.
Identification and expression of a new type II transmembrane protein in human mast cells. A cDNA encoding a new type II transmembrane protein has been isolated from...	13th January, 2006	Tanox, Inc., 10301 Stella Link Road, Suite 110, Houston, TX 77025, USA.	Genomics. 2005 Jul;86(1):68-75. Epub 2005 Apr 15. DOI Direct Link
→View more Tanox research publications.

Press Releases on Tanox:
New Report from PharmaPlus: HIV Pipelines & Deals	1st December, 2003	Pharmaplus	New Report from PharmaPlus: HIV Pipelines & Deals  At the end of November 2003 the joint United Nations Program on HIV/AIDS and the World Health Organization presented
Food Allergies: Drug makers set to capitalize?	1st July, 2003	Datamonitor	Food Allergies: Drug makers set to capitalize? Although food allergies have been recognized in the medical community since the beginning of the century, they have recently been
Wong’s BioTech Stock Report - outlook on allergic asthma (“asthma”)	1st May, 2003	Biotechsage	Wong’s BioTech Stock Report - outlook on allergic asthma (“asthma”) therapeutics
Biotech Tracker News - Xolair BLA Re-Submitted	1st August, 2001	Biotracker	Biotech Tracker News - Xolair BLA Re-Submitted  December 19,
Profile of Tanox	1st January, 1970	Biotracker	Biotech Tracker News - Profile of Tanox

BioNews Results for Tanox:
Cytovance Biologics Announces the Hiring of Dr. Jeffrey Su as Vice President of Bioanalytical Development to O	Pharma Live:  Aug 31 2009 2:56PM Matching: tanox

Tanox Clinical Trials:
TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1

Tanox Patents:
US Patent No.	Title
5428133	Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but notto IgE bound to FC receptors on basophils
5854400	Monoclonal antibodies which neutralize HIV-1 infection
5866129	Method of producing an antibody with a peptide corresponding to membrane-bound IgA
5872222	Conjugates of polymers and antibodies specific for T lymphocytes, and their use as adjuvants
5908626	Hybrid with interferon-.beta. and an immunoglobulin Fc joined by a peptide linker
→View more Tanox patents.

Tanox (TNOX) Financial information Links from Barchart
TNOX Quote from from Barchart.com
TNOX Chart from from Barchart.com
TNOX Profile from from Barchart.com
TNOX Opinion from from Barchart.com
→View more Tanox finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 969 times since April 2007, the link to the organisation's website has been followed 271 times

Recent Search Terms used to find this page: tanox anti-HIV | tanox houston | tanox houston | tanox building houston tx | tanox houston | tanox | tanox biotech | tanox houston tx | tanox Houston | tanox | .

Search for more companies in Houston

Search for more companies in TX

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Tanox